Apollomics, Inc. (APLM)
NASDAQ: APLM · Real-Time Price · USD
5.57
-0.15 (-2.62%)
Aug 6, 2025, 4:00 PM - Market closed

Company Description

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer.

The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways that is in Phase 1 dose escalation clinical trials to treat cancers within the brain.

Its immuno-oncology product candidates comprise APL-501, APL-502, and APL-801. The company was founded in 2015 and is based in Foster City, California.

Apollomics, Inc.
Apollomics logo
CountryUnited States
Founded2016
IndustryBiotechnology
SectorHealthcare
Employees13
CEOGuo-Liang Yu

Contact Details

Address:
989 East Hillsdale Blvd., Suite 220
Foster City, California 94404
United States
Phone650 209 4055
Websiteapollomicsinc.com

Stock Details

Ticker SymbolAPLM
ExchangeNASDAQ
Share ClassClass A Shares
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001944885
ISIN NumberKYG0411D1079
SIC Code2834

Key Executives

NamePosition
Dr. Guo-Liang Yu Ph.D.Co-Founder, Chief Executive Officer and Executive Chairman
Dr. Sanjeev Redkar MBA, Ph.D.Co-Founder and Executive Director
Dr. Matthew James Plunkett Ph.D.Chief Financial Officer

Latest SEC Filings

DateTypeTitle
Jul 25, 20256-KReport of foreign issuer
Apr 3, 202520-FAnnual and transition report of foreign private issuers
Apr 3, 20256-KReport of foreign issuer
Mar 31, 20256-KReport of foreign issuer
Jan 10, 2025SCHEDULE 13G/AFiling
Dec 20, 20246-KReport of foreign issuer
Dec 10, 20246-KReport of foreign issuer
Nov 14, 20246-KReport of foreign issuer
Nov 1, 20246-KReport of foreign issuer
Aug 15, 2024SC 13D/A[Amend] General statement of acquisition of beneficial ownership